Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3350486
Max Phase: Preclinical
Molecular Formula: C44H81N3O15P2
Molecular Weight: 954.09
Molecule Type: Small molecule
Associated Items:
ID: ALA3350486
Max Phase: Preclinical
Molecular Formula: C44H81N3O15P2
Molecular Weight: 954.09
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@@H](O)[C@@H]1O)OC(=O)CCCCCCCCCCCCCCC
Standard InChI: InChI=1S/C44H81N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-39(48)57-33-36(60-40(49)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)34-58-63(53,54)62-64(55,56)59-35-37-41(50)42(51)43(61-37)47-32-31-38(45)46-44(47)52/h31-32,36-37,41-43,50-51H,3-30,33-35H2,1-2H3,(H,53,54)(H,55,56)(H2,45,46,52)/t36-,37-,41-,42+,43-/m1/s1
Standard InChI Key: ITYHVANGBZMQML-VUYPABDGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 954.09 | Molecular Weight (Monoisotopic): 953.5143 | AlogP: 9.11 | #Rotatable Bonds: 40 |
Polar Surface Area: 265.49 | Molecular Species: ACID | HBA: 16 | HBD: 5 |
#RO5 Violations: 3 | HBA (Lipinski): 18 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 1.86 | CX Basic pKa: | CX LogP: 9.56 | CX LogD: 4.81 |
Aromatic Rings: 1 | Heavy Atoms: 64 | QED Weighted: 0.02 | Np Likeness Score: 0.84 |
1. Ryu EK, Ross RJ, Matsushita T, MacCoss M, Hong CI, West CR.. (1982) Phospholipid-nucleoside conjugates. 3. Syntheses and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5'-monophosphate-L-1,2-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5-diphosphate-L-1,2-diacylglycerols., 25 (11): [PMID:7143370] [10.1021/jm00353a010] |
2. Hong CI, An SH, Schliselfeld L, Buchheit DJ, Nechaev A, Kirisits AJ, West CR.. (1988) Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5'-diphosphate-1,2-dipalmitins., 31 (9): [PMID:3411602] [10.1021/jm00117a020] |
3. Hong CI, An SH, Buchheit DJ, Nechaev A, Kirisits AJ, West CR, Berdel WE.. (1986) Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids., 29 (10): [PMID:3761322] [10.1021/jm00160a041] |
Source(1):